RENAAL

RENAAL^? : Reduction of Endpoints in Noninsulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ;345(12):861-9. 11565518

Cette étude a inclus 1513 patients. Elle compare un ARA2^? (losartan) à un placebo. Le critère principal est l’incidence^? du critère combiné primaire (identique à celui de l’étude IDNT^?). La réduction est de -16 % pour le critère principal combiné et de -28 % pour la survenue d’IRT dans le groupe losartan comparé au placebo. L’étude démontre l’effet néphroprotecteur du losartan chez le diabétique de type 2 avec néphropathie

van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL. Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes Metab. 2016 Jun 23. 27337598

Felix Kröpelin T, de Zeeuw D, Holtkamp FA, Packham DK, L Heerspink HJ. Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. Nephrol Dial Transplant. 2016 Jan 19. pii : gfv429. 26790449

Vart P, Scheven L, Lambers Heerspink HJ, de Jong PE, de Zeeuw D, Gansevoort RT ; PREVEND^? Study Group and the RENAAL Investigators. Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging : A Prospective Longitudinal Cohort Study. Am J Kidney Dis. 2016 Jan ; 67(1):70-8. 26188433

Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol. 2015 Oct ; 80(4):678-86. 25872610

Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy : A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). Am J Kidney Dis. 2015 Sep ; 66(3):450-8. 25987260

McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy : a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis. 2014 Nov ; 64(5):714-22. 25064674

Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D. Estimated GFR decline as a surrogate end point for kidney failure : a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis. 2014 Feb ; 63(2):244-50. 24210590

Smink PA^?, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Lambers Heerspink HJ. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther. 2014 Feb ; 95(2):208-15. 24067744

Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, de Graeff PA, de Zeeuw D. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012 Aug ; 82(3):330-7. /22437412

Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy : results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012 Jan ; 59(1):75-83. 22051245

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy : a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011 Jun ; 32(12):1493-9. 21421598

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR^?, Brenner BM, de Zeeuw D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007 May ; 18(5):1540-6. 17409317

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM ; RENAAL Study Investigators. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy : the RENAAL study. Clin J Am Soc Nephrol. 2006 Jul ; 1(4):761-7. 17699284

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ^?, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM. Importance of baseline distribution of proteinuria in renal outcomes trials : lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol. 2005 Jun ; 16(6):1775-80. 15872078

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004 Aug 24 ; 110(8):921-7. 15302780

Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM ; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy : results from the RENAAL study. Arch Intern Med. 2003 Jul 14 ; 163(13):1555-65. 12860578

Thomas MC, Cooper ME, Shahinfar S, Brenner BM. Dialysis delayed is death prevented : a clinical perspective on the RENAAL study. Kidney Int. 2003 Apr ; 63(4):1577-9. 12631376

Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R ; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy : the RENAAL study. Kidney Int. 2003 Apr ; 63(4):1499-507. 12631367

Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S ; RENAAL Study Investigators. The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000 Dec ; 1(4):328-35. 11967819